Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk...

Area of Science:

• Pediatric Oncology
• Immunotherapy
• Cancer Vaccines

Background:

• Immunotherapy offers hope for high-risk cancers, but evidence in children is limited.
• Single-agent immunotherapy approaches have shown restricted efficacy in pediatric populations.
• Rarity of pediatric cancers complicates clinical trial design and evidence generation.

Purpose of the Study:

• To assess the effectiveness of a personalized dendritic cell (DC) vaccine as part of multimodal therapy.
• To evaluate the N-of-1 approach in a real-world setting for children with relapsed or high-risk solid tumors.
• To analyze survival outcomes and treatment synergy in pediatric cancer patients receiving DC vaccination.

Main Methods:

• Utilized an N-of-1 approach to evaluate personalized dendritic cell (DC) vaccines in pediatric patients.
• Collected data over a 4-year follow-up period for 48 patients with relapsed/high-risk solid tumors.
• Performed comparative survival analysis and assessed synergistic effects with other therapies.

Main Results:

• Overall survival for the cohort was 7.03 years.
• Disease control was achieved in 53.8% of patients post-vaccination.
• DC vaccination showed a significant survival benefit beyond 2 years and in patients with disease control (HR=0.53, P=.048; HR=0.16, P=.00053).
• Strong synergy was observed between DC vaccines and immune checkpoint inhibitors (ICIs) (HR=0.40, P=.0047).
• A trend towards synergistic effects was noted with metronomic cyclophosphamide and/or vinblastine (HR=0.60, P=.225).

Conclusions:

• Personalized DC vaccines are an effective component of multimodal, individualized treatment for pediatric solid tumors.
• The DC vaccine demonstrated efficacy in less advanced or indolent diseases with a good safety profile.
• DC vaccination synergized with both metronomic chemotherapy and immunomodulating agents, particularly ICIs.